ArticleMolecular & cellular proteomics : MCP2021
CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens.
Article in Molecular & cellular proteomics : MCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- CIITA-modified glioblastomas vaccinate and induce cross-protection against heterologous wild-type glioblastomas.Journal of translational medicine · 2025Article
- Deciphering the MHC immunopeptidome of human cancers with Ligand.MHC atlas.Briefings in bioinformatics · 2025Article
- NetMHCpan-4.2: improved prediction of CD8+ epitopes by use of transfer learning and structural features.Frontiers in immunology · 2025Article
- Article
- Long-range alternative splicing contributes to neoantigen specificity in glioblastoma.Briefings in bioinformatics · 2024Article
- Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer.Molecular therapy. Oncology · 2024Article
- The 2023 Report on the Proteome from the HUPO Human Proteome Project.Journal of proteome research · 2024Review
- The HLA-II immunopeptidome of SARS-CoV-2.Cell reports · 2024Article
- Novel vaccination strategies based on optimal stimulation of CD4Frontiers in immunology · 2024Article
- Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma.Cancers · 2023Article
- The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.Biomedical journal · 2023Review
- Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.PLoS pathogens · 2023Article
- A microfluidics-enabled automated workflow of sample preparation for MS-based immunopeptidomics.Cell reports methods · 2023Article
- Unraveling the glycosylated immunopeptidome with HLA-Glyco.Nature communications · 2023Article
- Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA.Frontiers in immunology · 2023Article
- Immunopeptidomics: Reading the Immune Signal That Defines Self From Nonself.Molecular & cellular proteomics : MCP · 2022Article
- Article
- HLA Allele-Specific Quantitative Profiling of Type 1 Diabetic B Lymphocyte Immunopeptidome.Journal of proteome research · 2022Article
- Beneficial autoimmunity improves cancer prognosis.Nature reviews. Clinical oncology · 2021Review
- Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD4+ T cell responses are crucial for inducing and maintaining effective anticancer immunity, and the identification of human leukocyte antigen class II (HLA-II) cancer-specific epitopes is key to the development of potent cancer immunotherapies. In many tumor types, and especially in glioblastoma (GBM), HLA-II complexes are hardly ever naturally expressed. Hence, little is known about immunogenic HLA-II epitopes in GBM. With stable expression of the class II major histocompatibility complex transactivator (CIITA) coupled to a detailed and sensitive mass spectrometry-based immunopeptidomics analysis, we here uncovered a remarkable breadth of the HLA-ligandome in HROG02, HROG17, and RA GBM cell lines. The effect of CIITA expression on the induction of the HLA-II presentation machinery was striking in each of the three cell lines, and it was significantly higher compared with interferon gamma (IFNɣ) treatment. In total, we identified 16,123 unique HLA-I peptides and 32,690 unique HLA-II peptides. In order to genuinely define the identified peptides as true HLA ligands, we carefully characterized their association with the different HLA allotypes. In addition, we identified 138 and 279 HLA-I and HLA-II ligands, respectively, most of which are novel in GBM, derived from known GBM-associated tumor antigens that have been used as source proteins for a variety of GBM vaccines. Our data further indicate that CIITA-expressing GBM cells acquired an antigen presenting cell-like phenotype as we found that they directly present external proteins as HLA-II ligands. Not only that CIITA-expressing GBM cells are attractive models for antigen discovery endeavors, but also such engineered cells have great therapeutic potential through massive presentation of a diverse antigenic repertoire.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.